Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Number of deaths and age-specific mortality rates for selected grouped causes, by age group and sex, 2000 to most recent year.

Abstract Mortality indicators for Brazilians aged between 10 and 24 years old were analyzed. Data were obtained from the Global Burden of Disease (GBD) 2019 Study, and absolute numbers, proportion of deaths and specific mortality rates from 1990 to 2019 were analyzed, according to age group (10 to 14, 15 to 19 and 20 to 24 years), sex and causes of death for Brazil, regions and Brazilian states. There was a reduction of 11.8% in the mortality rates of individuals aged between 10 and 24 years in the investigated period. In 2019, there were 13,459 deaths among women, corresponding to a reduction of 30.8% in the period. Among men there were 39,362 deaths, a reduction of only 6.2%. There was an increase in mortality rates in the North and Northeast and a reduction in the Southeast and South states. In 2019, the leading cause of death among women was traffic injuries, followed by interpersonal violence, maternal deaths and suicide. For men, interpersonal violence was the leading cause of death, especially in the Northeast, followed by traffic injuries, suicide and drowning. Police executions moved from 77th to 6th place. This study revealed inequalities in the mortality of adolescents and young adults according to sex, causes of death, regions and Brazilian states.

Number of deaths and mortality rates, by age group, sex, and place of residence, 1991 to most recent year.

To: State, territorial, tribal, and local policymakers and administrators of agencies and programs focused on child, youth, and family health and well-being Dear Colleagues, Thank you for your work to support children, youth, and families. Populations served by Administration for Children and Families (ACF)-funded programs — including victims of trafficking or violence, those who are unhoused, and young people and families involved in the child welfare system — are often at particularly high risk for substance use and overdose. A variety of efforts are underway at the federal, state, and local levels to reduce overdose deaths. These efforts focus on stopping drugs from entering communities, providing life-saving resources, and preventing drug use before it starts. Initiatives across the country are already saving lives: the overdose death rate has declined over the past year but remains too high at 32.6 per 100,000 individuals. Fentanyl, a powerful synthetic opioid, raises the risk of overdose deaths because even a tiny amount can be deadly. Young people are particularly at risk for fentanyl exposure, driven in part by widespread availability of counterfeit pills containing fentanyl that are marketed to youth through social media. While overdose deaths among teens have recently begun to decline, there were 6,696 deaths among adolescents and young adults in 2022 (the latest year with data available)[1], making unintentional drug overdose the second leading cause of death for youth ages 15—19 and the first leading cause of death among young adults ages 20-24.[2] Often these deaths happen with others nearby and can be prevented when opioid overdose reversal medications, like naloxone, are administered in time. CDC’s State Unintentional Drug Overdose Reporting System dashboard shows that in all 30 jurisdictions with available data, 64.7% of drug overdose deaths had at least one potential opportunity for intervention.[3] Naloxone rapidly reverses an overdose and should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It can be given as a nasal spray. Studies show that naloxone administration reduces death rates and does not cause harm if used on a person who is not overdosing on opioids. States have different policies and regulations regarding naloxone distribution and administration. Forty-nine states and the District of Columbia have Good Samaritan laws protecting bystanders who aid at the scene of an overdose.[4] ACF grant recipients and partners can play a critical role in reducing overdose deaths by taking the following actions: Stop Overdose Now (U.S. Centers for Disease Control and Prevention) Integrating Harm Reduction Strategies into Services and Supports for Young Adults Experiencing Homelessness (PDF) (ACF) Thank you for your dedication and partnership. If you have any questions, please contact your local public health department or state behavioral health agency. Together, we can meaningfully reduce overdose deaths in every community. /s/ Meg Sullivan Principal Deputy Assistant Secretary [1] Products - Data Briefs - Number 491 - March 2024 [2] WISQARS Leading Causes of Death Visualization Tool [3] SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC [4] Based on 2024 report from the Legislative Analysis and Public Policy Association (PDF). Note that the state of Kansas adopted protections as well following the publication of this report. Metadata-only record linking to the original dataset. Open original dataset below.

A quarter of the global human population is estimated to be latently infected by Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). TB remains the global leading cause of death by a single pathogen and ranks among the top-10 causes of overall global mortality. Current immunodiagnostic tests cannot discriminate between latent, active and past TB, nor predict progression of latent infection to active disease. The only registered TB vaccine, Bacillus Calmette-Guérin (BCG), does not adequately prevent pulmonary TB in adolescents and adults, thus permitting continued TB-transmission. Several Mtb proteins, mostly discovered through IFN-γ centered approaches, have been proposed as targets for new TB-diagnostic tests or -vaccines. Recently, however, we identified novel Mtb antigens capable of eliciting multiple cytokines, including antigens that did not induce IFN-γ but several other cytokines. These antigens had been selected based on high Mtb gene-expression in the lung in vivo, and have been termed in vivo expressed (IVE-TB) antigens. Here, we extend and validate our previous findings in an independent Southern European cohort, consisting of adults and adolescents with either LTBI or TB. Our results confirm that responses to IVE-TB antigens, and also DosR-regulon and Rpf stage-specific Mtb antigens are marked by multiple cytokines, including strong responses, such as for TNF-α, in the absence of detectable IFN-γ production. Except for TNF-α, the magnitude of those responses were significantly higher in LTBI subjects. Additional unbiased analyses of high dimensional flow-cytometry data revealed that TNF-α+ cells responding to Mtb antigens comprised 17 highly heterogeneous cell types. Among these 17 TNF-α+ cells clusters identified, those with CD8+TEMRA or CD8+CD4+ phenotypes, defined by the expression of multiple intracellular markers, were the most prominent in adult LTBI, while CD14+ TNF-α+ myeloid-like clusters were mostly abundant in adolescent LTBI. Our findings, although limited to a small cohort, stress the importance of assessing broader immune responses than IFN-γ alone in Mtb antigen discovery as well as the importance of screening individuals of different age groups. In addition, our results provide proof of concept showing how unbiased multidimensional multiparametric cell subset analysis can identify unanticipated blood cell subsets that could play a role in the immune response against Mtb.

Malaria is a major cause of illness and death particularly among children under five years. It was estimated that more than one million children living in Africa especially, in remote areas with poor access to health services die annually from the direct and indirect effects of malaria.

This is not a large dataset. The data in the dataset was gathered for four years by a data analyst from 2019-2022. This entails many purchases of antimalarial drugs for children, teenagers, and adults. It was produced manually from sales records and with inventory software in KOTZ PETHABAM PHARMACY LTD, Ogun state, Nigeria. The dataset has twelve columns and four rows.

****Task**** - Analyze the dataset of adults, teenagers and children.

• Give your observations about each category and which year or month shows a drastic increase in the number of cases of malaria.

• Analyze pre-covid malaria cases, post-covid and during covid malaria cases.

• How can the dataset be used to help community pharmacy to stock antimalaria drugs?

• Does seasons and weather condition have an impact on cases of malaria?

Footnote for table 1:a) UN Inter-agency Group for Child Mortality Estimation (2013) Levels & trends in child mortality.Report 2013. New York, UNICEF. 30 p.b) Child Health Epidemiology Reference Group.Child causes of death annual estimates by country, 2000–2010. Unpublished estimates available at http://cherg.org/datasets.html. Accessed 31 May 2013.c) UNICEF (2012) Pneumonia and diarrhoea: tackling the deadliest diseases for the world's poorest children.UNICEF: New York. 77 p.d) UNICEF (2013) State of the world's children 2013.Children with disabilities. UNICEF: New York. 164 p.